Skip to main content

Table 1 Summary of the CCL7 in cardiovascular disease in this review article

From: CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease

Cardiovascular disease References
Myocardial infarction CCL7↑ Risk of death↑/Recurrent myocardial infarction↑/Cardiac inflammation↑ [29,30,31]
CCL7 (MSCs) ↑ Cardiac remodeling↑ /Survival of HUVECs ↑/Myocardial inflammation↑ [32,33,34]
Cardiac hypertrophy CCL7↑ Inflammation (Early phase of cardiac hypertrophy) ↑ [35, 36]
Angiogenesis CCL7↑ Formation of blood vessels (Physiological condition) ↑ [37, 38]
Atherosclerosis In VSMCs and in carotid artery after balloon angioplasty CCL7↑
CCL7 (monocyte) ↑
Arterial thrombosis↑/-altered gut microbial diversity/VSMCs proliferation↑/Lipid accumulation in the aortas↑/ Endothelial expression of ICAM-1, CCL2, CCL7, IL-6, and IL-1β↑ [39,40,41,42,43,44,45]
Hypertension CCL7↑ 5-year transplant-free survival rates↓/Mononuclear cell and macrophage infiltration↑ [46,47,48,49]
Aortic aneurysm CCL7↑ M1 phenotype of macrophage (CCR1/JAK2/STAT1) ↑ [27, 50]
  1. HUVECs human umbilical vein endothelial cells, ICAM-1 intercellular adhesion molecule-1, IL-1β: interleukin-1β, IL-6: interleukin-6, MSCs mesenchymal stem cells, VSMCs vascular smooth muscle cells